Samuraciclib hydrochloride
Cat. No.：YN270058
CAS No. ：1805789-54-1
| 产品名称: | Samuraciclib hydrochloride |
| CAS No.: | 1805789-54-1 |
| Chemical Name: | (3R,4R)-4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-3-piperidinol, monohydrochloride |
| Synonyms: | CT7001 hydrochloride; ICEC0942 hydrochloride |
| 分子量: | 430.97 |
| 分子式: | C₂₂H₃₁ClN₆O |
| SMILES: | O[C@H]1CNCC[C@@H]1CNC2=NC3=C(C(C)C)C=NN3C(NCC4=CC=CC=C4)=C2.[H]Cl |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Samuraciclib hydrochloride (CT7001 hydrochloride) 是一种有效的，具有选择性，ATP 竞争性和口服活性的CDK7抑制剂，IC50为 41 nM。Samuraciclib hydrochloride 对CDK7的选择性分别是 CDK1，CDK2 (IC50为 578 nM)，CDK5 和 CDK9 的 45 倍，15 倍，230 倍和 30 倍。Samuraciclib hydrochloride 以 GI50值为 0.2-0.3 µM 来抑制乳腺癌细胞系的生 |
| IC50和靶点: | [{name:"CDK7:41 nM (IC50)"},{name: "CDK2:578 nM (IC50)"},{name: "CDK1:1.8 μM (IC50)"},{name: "CDK4:49 μM (IC50)"},{name: "CDK5:9.4 μM (IC50)"},{name: "CDK6:34 μM (IC50)"},{name: "CDK9:1.2 μM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Patel, H., Periyasamy, M., Sava, G.P., et al.ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatmentMol. Cancer Ther.17(6),1156-1166(2018)
